View More Recent Stories

Jun 25, 2019 01:00PM Artelo Biosciences Announces Closing of $8.0 Million Public Offering and Partial Exercise and Closing of Over-Allotment Option
Jun 21, 2019 01:54PM Aristotle (ARTL) Prices 1.3M Share Unit Offering at $6.15/Unit; Announces 1-for-8 Reverse Share Split
Jun 21, 2019 01:50PM Artelo Biosciences Announces Pricing of $8.0 Million Public Offering and Uplisting to Nasdaq
May 8, 2019 04:05PM Artelo Biosciences Retains Crescendo Communications, LLC for Investor Relations Services
Jan 3, 2019 08:00AM Artelo Biosciences Retains Maxim Group LLC to Provide Financial Advisory and Investment Banking Services
Oct 9, 2018 08:00AM New Preclinical Cell-Line Data of Artelo Biosciences' ART27.13 Demonstrate Anti-Proliferative Activity in Tumor Models
Jul 3, 2018 08:00AM Artelo Biosciences Announces Five Year Commitment To Sponsor The Young Investigator Award At The International Cannabinoid Research Society Annual Symposium
Jun 12, 2018 08:00AM Artelo Biosciences Enters Into Global R&D Partnership With Syngene International And Aptus Clinical For The Clinical Development Of ART27.13 In Oncology
May 30, 2018 08:00AM Artelo Biosciences Commences Trading On OTCQB
Apr 18, 2018 08:00AM Artelo Biosciences And Stony Brook University Announce Worldwide License Agreement For Portfolio Of Fatty Acid Binding Protein Inhibitor Drug Candidates
View More Recent Stories